Backing a Potential Aesthetic Blockbuster
Fibrocell Brings in $22.8M to Launch Injectable laViv in U.S.
By Marie Powers
Wednesday, August 24, 2011
On Tuesday, Fibrocell Science Inc. appeared to swim against the tide of nervous capital markets, raising $22.8 million through a private placement of 41,409,458 shares of common stock at a purchase price of 55 cents per share.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.